Efficacy and Safety of Antiplatelet Agents for Adult Patients With Ischemic Moyamoya Disease
Authors:
Open Access
- 15 January 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 11
Abstract
Background: The use of antiplatelet agents in ischemic moyamoya disease (MMD) is controversial. This study aimed to investigate the effectiveness and safety of antiplatelet therapy compared with conservative treatment and surgical revascularization in ischemic MMD patients.Methods: Ischemic MMD patients were retrospectively enrolled from eight clinical sites from January 2013 to December 2018. Follow-up was performed through clinical visits and/or telephone interviews from first discharge to December 2019. The primary outcome was the episodes of further ischemic attacks, and the secondary outcome was the individual functional status. Risk factors for future stroke were identified by the LASSO-Cox regression model. Propensity score matching was applied to assemble a cohort of patients with similar baseline characteristics using the TriMatch package.Results: Among 217 eligible patients, 159 patients were included in the analyses after a 1:1:1 propensity score matching. At a mean follow-up of 33 months, 12 patients (7.5%) developed further incident cerebral ischemic events (surgical:antiplatelet:conservative = 1:3:8; p = 0.030), 26 patients (16.4%) developed a poor functional status (surgical:antiplatelet:conservative = 7:12:7; p = 0.317), and 3 patients (1.8%) died of cerebral hemorrhage (surgical:antiplatelet:conservative = 1:2:0; p = 0.361). The survival curve showed that the risk of further cerebral ischemic attacks was lowest with surgical revascularization, while antiplatelet therapy was statistically significant for preventing recurrent risks compared with conservative treatment (χ2 = 8.987; p = 0.011). No significant difference was found in the functional status and bleeding events. The LASSO-Cox regression model revealed that a family history of MMD (HR = 6.93; 95% CI: 1.28–37.52; p = 0.025), a past history of stroke or transient ischemic attack (HR = 4.35; 95% CI: 1.09–17.33; p = 0.037), and treatment (HR = 0.05; 95% CI: 0.01–0.32; p = 0.001) were significantly related to the risk of recurrent strokes.Conclusions: Antiplatelet agents were effective and safe in preventing further cerebral ischemic attacks in adult patients with ischemic MMD. They may be a replacement therapy for patients with surgical contraindications and for patients prior to revascularization.Keywords
Funding Information
- National Natural Science Foundation of China (81471180, 81671132, 81701142)
This publication has 32 references indexed in Scilit:
- Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic AttackStroke, 2014
- Epidemiology of Moyamoya Disease in TaiwanStroke, 2014
- Incidence, Prevalence, and Survival of Moyamoya Disease in KoreaStroke, 2014
- Moyamoya Disease in ChinaStroke, 2012
- Guidelines for Diagnosis and Treatment of Moyamoya Disease (Spontaneous Occlusion of the Circle of Willis)Neurologia medico-chirurgica, 2012
- Moyamoya Disease and Moyamoya SyndromeNew England Journal of Medicine, 2009
- Moyamoya Disease in EuropeansStroke, 2008
- Novel epidemiological features of moyamoya diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Prevalence and Clinicoepidemiological Features of Moyamoya Disease in JapanStroke, 2008
- Clinical Features of Moyamoya Disease in the United StatesStroke, 1998